[Clinical experiences in liver diseases (specially in patients with fatty liver due to alcoholism and food poisoning) under monotherapy with ornithine aspartate].
D000293:Adolescent; D000328:Adult; D000437:Alcoholism / Q000150:complications*; D001224:Aspartic Acid / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004151:Dipeptides / Q000627:therapeutic use*; D004361:Drug Tolerance; D005234:Fatty Liver / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D005517:Foodborne Diseases / Q000150:complications*; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009952:Ornithine / Q000627:therapeutic use
D004151:Dipeptides; D001224:Aspartic Acid; D009952:Ornithine
Klinische Erfahrungen bei Hepatopathien(insbesondere bei Patienten mit alkoholtoxisch und nutritivtoxisch bedingter Fettleber) unter der monotherapie mit Ornithin-aspartat.